Contineum Therapeutics, Inc.
CTNMNASDAQHealthcareBiotechnology
Previous close
$17.19
+$1.17 · +7.30%
CTNM company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
25
Expensive
Momentum
63
Gaining
Sentiment
49
Mixed
Risk resilience
54
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteContineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Carmine N. Stengone
- Listed since
- Apr 4, 2024
- Employees
- 51
Market position
Day range
Current $17.19
52-week range
Current $17.19
- Open
- $15.985
- Previous close
- $16.02
- Volume
- 353.91K
- 0.98× average
- Average volume
- 360.16K
- Average daily volume
- Market cap
- 646.71M USD
- Beta
- 0.74
- Market reference 1
- 50-day average
- $14.4158
- +19.24% above average
- 200-day average
- $13.2061
- +30.17% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 249.27M USD
- P/E (TTM)
- -9.94×
- P/B (TTM)
- 2.69×
- P/S (TTM)
- 0×
- EV / EBITDA
- -3.68×
- Earnings yield
- -18.94%
- Free cash flow yield
- -17.54%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -22.98%
- Return on assets
- -21.68%
- Return on invested capital
- -25.28%
Financial health
- Debt / equity
- 0.03×
- Current ratio
- 27.5×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | 50M USD | — | — |
| Cost of goods sold | — | 258K USD | — | — | — |
| Gross profit | — | −258K USD | 50M USD | — | — |
| Research and development | 51.52M USD | 38.16M USD | 27.6M USD | 16.89M USD | 22.36M USD |
| Selling, general, and administrative | 16.54M USD | 12.47M USD | 6.32M USD | 5.83M USD | 6.29M USD |
| Operating expenses | 68.06M USD | 50.64M USD | 66.08M USD | 22.72M USD | 28.65M USD |
| Interest income | 8.25M USD | 8.91M USD | 4.61M USD | 761K USD | 77K USD |
| Interest expense | — | — | 208K USD | 388K USD | 332K USD |
| Depreciation and amortization | 323K USD | 258K USD | 195K USD | 329K USD | 325K USD |
| Operating income | −68.06M USD | −50.89M USD | −16.08M USD | −22.72M USD | −28.65M USD |
| Net income | −59.98M USD | −42.26M USD | 22.72M USD | −24.25M USD | −29M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 50%
- 5 beats, 5 misses, 0 met estimates
- Average EPS surprise
- -66.51%
- 10 comparable reports
- Latest EPS result
- -0.4
- Estimate -0.45 · Beat by 10.87%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Recent analyst actions
CTNM news
CTNM peers
ETFs holding CTNM
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI15.22M0.00%2.3T USD0.03%$378.24+0.44%
iShares Russell 2000 ETFIWM10.49M0.01%81.62B USD0.19%$299.96+0.77%
Vanguard Extended Market ETFVXF4.7M0.00%93.7B USD0.05%$245.53+0.82%
iShares Russell 2000 Value ETFIWN4.06M0.03%14.66B USD0.24%$224.81+0.45%
iShares Biotechnology ETFIBB3.46M0.03%10.75B USD0.44%$213.56+1.29%
Vanguard Russell 2000 ETFVTWO2.34M0.01%17.4B USD0.06%$121.25+0.74%
Schwab U.S. Small-Cap ETFSCHA2M0.01%23.1B USD0.03%$34.83+0.52%
iShares Micro-Cap ETFIWC1.48M0.10%1.53B USD0.60%$198.39+1.10%Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 15.22M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
iShares Russell 2000 ETFIWM- Market value
- 10.49M
- Weight
- 0.01%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
Vanguard Extended Market ETFVXF- Market value
- 4.7M
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Russell 2000 Value ETFIWN- Market value
- 4.06M
- Weight
- 0.03%
- AUM
- 14.66B USD
- Expense ratio
- 0.24%
- Price / 1D
- $224.81+0.45%
iShares Biotechnology ETFIBB- Market value
- 3.46M
- Weight
- 0.03%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
Vanguard Russell 2000 ETFVTWO- Market value
- 2.34M
- Weight
- 0.01%
- AUM
- 17.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $121.25+0.74%
Schwab U.S. Small-Cap ETFSCHA- Market value
- 2M
- Weight
- 0.01%
- AUM
- 23.1B USD
- Expense ratio
- 0.03%
- Price / 1D
- $34.83+0.52%
iShares Micro-Cap ETFIWC- Market value
- 1.48M
- Weight
- 0.10%
- AUM
- 1.53B USD
- Expense ratio
- 0.60%
- Price / 1D
- $198.39+1.10%
Continue in GoAI
Research CTNMresearch.disclaimer